(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 9.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Apellis Pharmaceuticals's revenue in 2025 is $754,649,000.On average, 9 Wall Street analysts forecast APLS's revenue for 2025 to be $111,589,764,476, with the lowest APLS revenue forecast at $89,084,902,514, and the highest APLS revenue forecast at $129,838,656,471. On average, 9 Wall Street analysts forecast APLS's revenue for 2026 to be $108,471,792,888, with the lowest APLS revenue forecast at $95,702,493,798, and the highest APLS revenue forecast at $119,879,434,168.
In 2027, APLS is forecast to generate $130,191,510,480 in revenue, with the lowest revenue forecast at $116,679,247,849 and the highest revenue forecast at $143,418,610,493.